← Back to Search

Biological Response Modifier

Thymalfasin for COVID-19 (Ta1 Trial)

Phase 2

Waitlist Available

Research Sponsored by Inova Health System

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

Ta1 Trial Summary

This trial will test whether or not Thymalfasin (thymosin alpha 1 or Ta1), can help reduce the rate and severity of infection with COVID-19 in patients with end-stage renal disease (ESRD) who are on hemodialysis.

Eligible Conditions

COVID-19
Coronavirus

Ta1 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Reduction in documented infection with COVID-19 Reduction in infection with COVID-19

Secondary outcome measures

Change in any existing comorbidities or occurrence of newly diagnosed disease

Change in lymphocyte subsets (CD4, CD8)

Duration of mechanical ventilation

+11 more

Ta1 Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Active armExperimental Treatment1 Intervention

1.6 mg thymalfasin in 1 mL subcutaneous injection twice weekly after dialysis for 8 weeks

Group II: Control armActive Control1 Intervention

Standard care

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Inova Health SystemLead Sponsor

2 Previous Clinical Trials

778 Total Patients Enrolled

1 Trials studying COVID-19

650 Patients Enrolled for COVID-19

Inova Health Care ServicesLead Sponsor

69 Previous Clinical Trials

21,997 Total Patients Enrolled

2 Trials studying COVID-19

759 Patients Enrolled for COVID-19

Davita Clinical ResearchIndustry Sponsor

22 Previous Clinical Trials

15,241 Total Patients Enrolled

2 Trials studying COVID-19

2,727 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any comparable assessments regarding Thymalfasin?

"Presently, there are 3 active investigations into Thymalfasin with 1 trial in its final stage. While the majority of clinical trials occur within Kansas City, Kansas, other sites around America are also involved."

Answered by AI

Has Thymalfasin obtained regulatory acceptance from the FDA?

"Data from Phase 2 clinical trials have shown that Thymalfasin is somewhat safe, so it was given a score of two. Unfortunately, no data exists yet to measure its efficacy in humans."

Answered by AI

What indications has Thymalfasin been found to effectively address?

"Thymalfasin is often employed to manage adjuvant therapy, hepatitis b virus infections, chronic conditions, and the administration of vaccines."

Answered by AI

Is there still capacity for applicants in this trial?

"At this moment, no individuals are being recruited for the trial which was initially published on December 1st 2021 and most recently updated on September 24th 2022. If you're looking for alternative trials related to COVID-19 or Thymalfasin, there are 1717 clinical studies accepting participants with coronavirus symptoms as well as 3 dedicated research efforts recruiting volunteers."

Answered by AI

What is the magnitude of participation in this experiment?

"This examination is not currently open for participant registration. It was initially published on 1/12/2021 and edited most recently on 9/24/2022. For alternative studies, 1717 trials are actively seeking participants with COVID-19 and 3 investigations related to Thymalfasin demand volunteers."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients

William B. Ershler, MD 2021. "Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04428008.

All > Dialysis > Covid